Chemkart India shares list on a flat note at ₹250 on BSE SME. Details here
However, within minutes of listing, Chemkart India share price extended gains as it rose to the day's high of ₹ 257.90, recording a 4% rise over the initial public offering (IPO) price.
The listing was largely in line with the grey market premium (GMP) trends. Chemkart India IPO GMP was ₹ 3, signalling a 1% listing pop for the company shares.
Chemkart India IPO had witnessed a decent demand for its IPO during the bidding process, which opened on July 7 and closed on July 9.
At the end of the subscription period, Chemkart India IPO was booked 5.91 times. The individual investor portion was booked 1.63 times, and the non-institutional investor (NII) portion was subscribed 5.64 times. The qualified institutional buyer (QIB) portion was booked the most at 13.69 times.
Chemkart India IPO was a book-building offer of ₹ 80.08 crore. The issue was a combination of a fresh issue of ₹ 64.48 crore and an offer for sale of ₹ 15.60 crore.
The company plans to use the funds raised for financing the expenditure towards setting up a manufacturing facility through investment in a wholly-owned subsidiary, repayment of certain borrowings availed by the company and for general corporate purposes.
Smart Horizon Capital Advisors Private Limited was the book-running lead manager of the Chemkart India IPO, while Bigshare Services Pvt Ltd acted as the registrar for the issue.
Chemkart India is a distributor of high-quality food and health ingredients. The company targets the B2B platform, providing products for manufacturing supplements like sports, health, vitamins, and protein.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
42 minutes ago
- Economic Times
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi
Synopsis Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US. Reuters Sun pharma logo( File photo) Sun Pharmaceutical Industries on Monday said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for severe hair the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement. As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added. Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license, it stated. Other specific terms of the settlement and license agreement are confidential, it added. In a separate statement, the drug firm announced the launch of Leqselvi (8 mg) tablets in the US medication (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata."The launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," Richard Ascroft, CEO of Sun Pharma North America, said."As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," he added. Shares of Sun Pharma ended 0.54 per cent higher at Rs 1,681.45 apiece on the BSE.
Mint
3 hours ago
- Mint
GAIL signs 10-year LNG supply deal with Vitol, extends pact with Oil India
New Delhi: State-run GAIL (India) Ltd has signed a long-term LNG sales and purchase agreement with Vitol Asia Pte. Ltd for the annual supply of approximately 1 million metric tonnes per annum (MMTPA) of liquefied natural gas over a 10-year period, starting in 2026. Under the agreement, Vitol will deliver LNG to GAIL from its global portfolio, the company said in a statement. 'GAIL is expanding its long-term LNG portfolio to meet demand growth. We are pleased to partner with Vitol Asia Pte. Ltd, and this agreement represents a key milestone in reinforcing GAIL's capability to reliably serve its diverse and evolving customer base,' said Sanjay Kumar, director (Marketing), GAIL. Jay Ng, chief financial officer of Vitol Asia and a member of its executive committee, said that the growing Indian market is core to Vitol's strategy and its diversified portfolio enables it to offer India a stable supply of cleaner and competitive energy. India was the world's fourth-largest LNG importer in 2024, and demand is expected to continue rising steadily over the next decade. The central government has set a target to raise the share of natural gas in the country's primary energy mix from the current 6% to 15% by 2030. As part of this vision, India's LNG regasification capacity has nearly doubled from 21 MMTPA in 2014. Separately, on 9 July, GAIL also signed an agreement with Oil India Ltd to extend their existing gas sale and purchase pact by another 15 years, effective from 1 July 2025. Under the revised agreement, Oil India will supply up to 900,000 standard cubic meters per day (SCMD) of natural gas from its Bakhri Tibba block in Rajasthan. GAIL currently owns and operates a 16,421-km network of natural gas pipelines across the country, transmitting more than 127 million standard cubic meters per day (MMSCMD) of gas in FY25. It is also executing multiple pipeline projects to expand this network further. The company operates a gas-based petrochemical complex at Pata and holds an LNG portfolio of 16.56 MMTPA, accounting for 61% of India's total LNG imports. GAIL reported a consolidated net profit of ₹ 2,491.76 crore for the January-March quarter of FY25, compared with ₹ 2,468.71 crore in the same quarter a year earlier. Shares of GAIL closed at ₹ 183.65 on the BSE on Monday, up 0.93% from the previous close.
The Print
3 hours ago
- The Print
Sensex, Nifty fall for 4th day on selling in IT shares, foreign fund outflows
The 50-share NSE Nifty settled lower by 67.55 points or 0.27 per cent to 25,082.30. The 30-share BSE Sensex dropped by 247.01 points or 0.30 per cent to settle at 82,253.46. During the day, it fell 490.09 points or 0.59 per cent to 82,010.38 but recovered some of the losses towards the close. Mumbai, Jul 14 (PTI) Benchmark stock indices Sensex and Nifty declined on Monday, extending the losing run to the fourth day amid selling in IT shares and foreign fund outflows. Sensex has dropped nearly 1,460 points or 1.75 per cent and Nifty by 440 points or 1.73 per cent in the four days of fall since July 9. Among Sensex firms, Asian Paints fell the most by 1.58 per cent. Tech Mahindra, Bajaj Finance, Infosys, HCL Tech, Tata Consultancy Services, Larsen & Toubro and Tata Motors were among the laggards. However, Eternal, Titan, Mahindra & Mahindra and ITC were among the gainers. Foreign Institutional Investors (FIIs) offloaded equities worth Rs 5,104.22 crore on Friday, according to exchange data. The broader indices, however, outperformed the benchmark, with midcap and smallcap indices gaining between 0.71 per cent and 1.04 per cent. 'Consolidation continued in the domestic market as the tariff headlines and a subdued start to the earnings season are influencing investors to be more sensitive with valuation trading at 3 yrs high level,' Vinod Nair, Head of Research, Geojit Investments, said. However, stock-specific action continues with sector-wise pick-up in healthcare, realty, consumer & discretionary, while IT remains the laggard due to the risk of earnings downgrades in FY26, Nair added. An Indian commerce ministry team has reached Washington for another round of talks on the proposed bilateral trade agreement (BTA), which will begin on Monday, an official said. 'Markets started the week on a volatile note and extended their recent decline, ending nearly half a per cent lower. After an initial dip, the Nifty attempted to stabilize in early trade, but sustained pressure from heavyweight stocks dragged the index down as the session progressed,' Ajit Mishra – SVP, Research, Religare Broking Ltd, said. The BSE midcap gauge climbed 0.67 per cent and smallcap index edged higher by 0.57 per cent. BSE Focused IT dropped 1.07 per cent, IT by 0.99 per cent, teck by 0.79 per cent and industrials by 0.24 per cent. Realty surged 1.38 per cent, healthcare jumped 1.15 per cent, consumer discretionary (0.54 per cent), commodities (0.24 per cent) and power (0.24 per cent). As many as 2,137 stocks declined while 2,054 advanced and 149 remained unchanged on the BSE. In Asian markets, South Korea's Kospi, Shanghai's SSE Composite index and Hong Kong's Hang Seng settled in the positive territory while Japan's Nikkei 225 index ended lower. European markets were trading in negative territory. The US markets ended lower on Friday. Wholesale price inflation (WPI) turned negative after a gap of 19 months, declining 0.13 per cent in June as deflation widened in food articles and fuel, along with softening in manufactured product costs, government data showed on Monday. Retail inflation slipped to a more than six-year low of 2.1 per cent in June mainly due to subdued prices of food items, including vegetables, pulses, meat, and milk. Global oil benchmark Brent crude climbed 0.99 per cent to USD 71.06 a barrel. PTI SUM MR MR This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
